No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

TheStreet. Telemedicine company GoodRx (GDRX) has been helping Americans find the cheapest way to buy drugs for years. Thanks ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...